New pharmacotherapeutic treatment options for crack-cocaine dependent people in the Netherlands.|
|- candidate number||8574|
|- NTR Number||NTR2576|
|- ISRCTN||ISRCTN wordt niet meer aangevraagd.|
|- Date ISRCTN created|
|- date ISRCTN requested|
|- Date Registered NTR||21-okt-2010|
|- Secondary IDs||2009-010584-16 EudraCT|
|- Public Title||New pharmacotherapeutic treatment options for crack-cocaine dependent people in the Netherlands.|
|- Scientific Title||New pharmacotherapeutic treatment options for crack-cocaine dependent people in the Netherlands.|
|- hypothesis||Treatment retention of crack cocaine dependent patients increases when a pharmacological agent is added to standard outpatient psychosocial treatment.|
|- Healt Condition(s) or Problem(s) studied||Psycho-social intervention, Topiramate , Cocain addiction, Crack cocaine, Modafinil, Dexamphetamine SR|
|- Inclusion criteria||In the sub-studies of topiramate and modafinil, eligible patients must:|
1. Be at least 18 years old;
2. Be cocaine dependent (DSM-IV) during at least the previous year;
3. Use cocaine on a regular basis (i.e., >= 8 days) in the previous month;
4. Administer their illicit cocaine primarily by means of basing ('crack');
5. Be able and willing to participate in outpatient psycho-social treatment and associated assessments;
6. Have provided written informed consent with regard to their assigned study treatment.
In the sub-study with dexamphetamine SR, the minimal duration of cocaine dependency will be five years instead of one year. In addition, these patients have to meet one extra inclusion criterion:
7. A history of earlier failed treatments aimed at reducing, or abstaining from, cocaine use ('treatment-refractory').
|- Exclusion criteria||Patients will be excluded in case of:|
1. Severe medical (e.g., severe renal or kidney insufficiency/failure) or psychiatric problems (e.g. acute psychosis, current major depression, suicidal), which constitute a contra-indication for participation;
2. Cardiovascular problems (ECG);
3. Pregnancy or continued lactation;
4. Indication for treatment with naltrexone, disulfiram, or acamprosate;
5. Anticipated necessity of residential treatment (clinical judgement);
6. Insufficient command of the Dutch language;
7. Current participation in another addiction treatment trial.
|- mec approval received||yes|
|- multicenter trial||yes|
|- Type||2 or more arms, randomized|
|- planned startdate ||1-apr-2010|
|- planned closingdate||1-apr-2014|
|- Target number of participants||216|
|- Interventions||Psychosocial treatment (treatment as usual; TAU) compared with TAU added with experimental medication.
The intervention will study the effect of Topiramate, Dexamphetamine and Modafinil, as an add-on to a weekly outpatient psychosocial treatment as usual (TAU). The medications will be prescribed during the 12-week study period. Topiramate will be investigated in Brijder and will be titrated to a maximum oral dose of 200 mg/ day. Dexamphetamine will be studied in Bouman GGZ in sustained-release form in a daily, oral fixed dose of 60 mg. In Arkin, Modafinil will be prescribed in a fixed oral dose of 400 mg/ day.
|- Primary outcome||Data will be analysed following an intention-to-treat approach, consisting of all randomised patients that received TAU with at least one dose of the prescribed medication (experimental groups) or TAU only (control groups). The primary outcome measure is treatment retention, defined as the number of weeks attended following the start of treatment. In each sub-study, the treatment groups will be compared on length of treatment until dropping out or termination, using a Cox proportional hazards regression model. Compliance with the study medication can only be investigated in the experimental conditions. |
|- Secondary outcome||Secondary effects of the interventions will be evaluated in terms of safety, illicit cocaine use, cocaine craving, use of other substances, physical and mental health, social functioning (including criminality), and patient satisfaction. Pre- to post-treatment changes in illicit cocaine use, defined as the number of illicit cocaine using days in the month preceding the assessment, will be compared between the two study groups in each sub-study using a 2 (time) x 2 (group) repeated measures ANOVA. Similar analyses will be conducted for changes in substance use other than cocaine, and for other continuous and Likert-scaled outcome measures. |
|- Timepoints||1. Assessment at baseline, four, eight and twelve weeks;|
2. Urinalysis at week 9-12.
|- Trial web site||N/A|
|- status||stopped: trial finished|
|- CONTACT FOR PUBLIC QUERIES||MSc Mascha Nuijten|
|- CONTACT for SCIENTIFIC QUERIES||Dr. Vincent Hendriks|
|- Sponsor/Initiator ||Academic Medical Center (AMC), Amsterdam|
(Source(s) of Monetary or Material Support)
|ZON-MW, The Netherlands Organization for Health Research and Development|
|- Publications||1. Nuijten, M., Blanken, P., Van de Wetering, B., Nuijen, B., Van den Brink, W., & Hendriks, V. (2016). Sustained- release dexamphetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled, double-blind trial. The Lancet, in press. DOI: http://dx.doi.org/10.1016/S0140-6736(16)00205-1.
2. Nuijten, M., Blanken, P., Van den Brink, W., & Hendriks, V. (2015). Modafinil in the treatment of crack-cocaine dependence in the Netherlands: Results of an open-label randomised controlled feasibility trial. Journal of Psychopharmacology, 29, 678-687.
3. Nuijten, M., Blanken, P., Van den Brink, W., & Hendriks, V. (2014). Treatment of crack-cocaine dependence with topiramate: A randomized controlled feasibility trial in The Netherlands. Drug and Alcohol Dependence, 138, 177-184.
4. Nuijten, M., Blanken, P., Van den Brink, W., & Hendriks, V. (2011). Cocaine Addiction Treatments to improve Control and reduce Harm (CATCH): New Pharmacological Treatment Options for Crack-Cocaine Dependence in the Netherlands. BMC Psychiatry, 11:135.
|- Brief summary||Crack-cocaine has become one of the drugs of most concern in the Netherlands, being associated with a wide range of medical, psychiatric and social problems for the individual. Despite this status as one of the most problematic addictions, available treatment options for cocaine dependent users are limited at best. Psycho-social interventions for cocaine dependence generally show modest results, and there are no proven effective pharmacotherapies to date, despite the wide range of medications tested for this specific type of dependence, among others in the United States. The overall objective of this pharmacotherapeutic feasibility study is to investigate various potentially efficacious medications for their usefulness in the treatment of cocaine dependence, and – dependent upon the results – to yield one or more candidate medications for future investigation in a large-scale confirmatory controlled trial. The intervention study aims to evaluate, in crack dependent patients willing to participate in one of the new pharmacotherapies, the response to medically prescribed oral topiramate (Brijder Verslavingszorg, The Hague), oral modafinil (Jellinek/Mentrum, Amsterdam), and oral dexamphetamine SR (BoumanGGZ, Rotterdam), as an add-on to psychosocial treatment-as-usual (TAU), compared to TAU alone, in terms of acceptance, retention, compliance, potential efficacy, safety, and patient satisfaction.|
|- Main changes (audit trail)||For the feasibility study on dexamphetamine SR, a protocol with substantial changes was submitted to the medical ethical committee (MEC) as a new project, which has recently been approved by the MEC (EudraCT-number 2013-004024-11; project NL46415.018.13). Major changes that have been made to the sub-study of SR dexamphetamine are:|
1) The study will evaluate, in crack dependent patients with comorbid heroin dependence, the response to medically prescribed oral dexamphetamine SR (60 mg/day) as an add-on to heroin assisted treatment, in terms of potential efficacy, acceptance, compliance, safety, and patient satisfaction.
2) The study design has been changed to a multicenter, double-blind, placebo-controlled, randomized trial. Following screening and baseline assessment, eligible patients in a heroin-assisted maintenance treatment program will be randomly allocated by the collaborating pharmacist to (continued) heroin-assisted treatment plus 12 weeks treatment with placebo (control group; n=36) or to (continued) heroin-assisted treatment plus 12 weeks treatment with sustained release dexamphetamine 60 mg/day (experimental group; n=36).
3) The addiction treatment organizations that participate in the present study are: Brijder Verslavingszorg (The Hague: 1 study site), BoumanGGZ/Antes (Rotterdam: 1 study site), and GGD Amsterdam (Amsterdam: 2 study sites).
4) The primary outcome measure is defined as cocaine use, defined as the total number of days of crack-cocaine use during the 12 weeks study period (range: 0 – 84 days), and will be analyzed in a multivariate regression analysis, controlling for study group and treatment site interactions.
|- RECORD||21-okt-2010 - 4-apr-2016|
- Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar firstname.lastname@example.org